Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 23;2(20):2783-2786.
doi: 10.1182/bloodadvances.2018015859.

Emicizumab should be prescribed independent of immune tolerance induction

Sandra Le Quellec  1   2 , Claude Negrier  1   2
Affiliations

Emicizumab should be prescribed independent of immune tolerance induction

Sandra Le Quellec et al. Blood Adv. .

Abstract

This article has a companion Point by Young.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.L.Q. has received grants and/or honoraria for lectures from and/or has served on advisory boards at CSL Behring, LFB, Shire, and SOBI. C.N. has received research grants from and/or honoraria for lectures and/or has served on advisory boards at Alnylam, Baxalta/Shire, Bayer, CSL Behring, LFB, Novo Nordisk, Octapharma, Pfizer, and Roche.

References

    1. Gouw SC, van der Bom JG, Ljung R, et al. ; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231-239. - PubMed
    1. Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374(21):2054-2064. - PubMed
    1. Calvez T, Chambost H, Claeyssens-Donadel S, et al. ; FranceCoag Network. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124(23):3398-3408. - PubMed
    1. Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia. 2010;16(1):90-100. - PubMed
    1. Morfini M, Auerswald G, Kobelt RA, et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia. 2007;13(5):502-507. - PubMed

MeSH terms